Cell-penetrating apoptotic peptide/p53 DNA nanocomplex as adjuvant therapy for drug-resistant breast cancer

Molecular Pharmaceutics

Volumn 11, Issue 10, 2014, Pages 3352-3360

  Wang, Huiyuan ^a   Wang, Huixin ^a   Liang, Jianming ^a,b   Jiang, Yifan ^a   Guo, Qianqian ^a   Peng, Huige ^a   Xu, Qin ^b   Huang, Yongzhuo ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

apoptosis; apoptotic peptide; AVPI; breast cancer; cell penetrating peptide; drug resistance; p53

Indexed keywords

APOPTOSIS INDUCING FACTOR; AVPIR8 P53 DNA NANOCOMPLEX; CASPASE 3; CELL PENETRATING PEPTIDE; DOXORUBICIN; PROCASPASE 3; PROTEIN P53; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TETRAPEPTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; PARTICLE SIZE; SOLID PHASE SYNTHESIS; TUMOR GROWTH; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; WEIGHT CHANGE; ZETA POTENTIAL; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; GENETICS; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; DNA; DOXORUBICIN; FEMALE; HUMANS; MICE; MICE, NUDE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907964036     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp5001058     Document Type: Article

References (28)

1. Gul, O.; Basaga, H.; Kutuk, O. Apoptotic blocks and chemotherapy resistance: strategies to identify Bcl-2 protein signatures Briefings Funct. Genomics Proteomics 2008, 7 (1) 27-34
2. Colombo, P. E.; Milanezi, F.; Weigelt, B.; Reis-Filho, J. S. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction Breast Cancer Res. 2011, 13 (3) 212
3. Rivera, E.; Gomez, H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone Breast Cancer Res. 2010, 12 (Suppl. 2) S2
4. Moreno-Aspitia, A.; Perez, E. A. Treatment options for breast cancer resistant to anthracycline and taxane Mayo Clin. Proc. 2009, 84 (6) 533-45
5. Wong, R. S. Apoptosis in cancer: from pathogenesis to treatment J. Exp. Clin. Cancer Res. 2011, 30, 87
6. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144 (5) 646-74
7. Brown, J. M.; Attardi, L. D. The role of apoptosis in cancer development and treatment response Nat. Rev. Cancer 2005, 5 (3) 231-7
8. Lane, D. P.; Cheok, C. F.; Lain, S. p53-based cancer therapy Cold Spring Harbor Perspect. Biol. 2010, 2 (9) a001222
9. Indran, I. R.; Tufo, G.; Pervaiz, S.; Brenner, C. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells Biochim. Biophys. Acta 2011, 1807 (6) 735-45
10. Wang, X.; Wu, X.; Wang, C.; Zhang, W.; Ouyang, Y.; Yu, Y.; He, Z. Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-kappaB pathway in MCF-7 cells FEBS Lett. 2010, 584 (15) 3392-7
11. Qi, X.; Chang, Z.; Song, J.; Gao, G.; Shen, Z. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin Anticancer Drugs 2011, 22 (6) 556-62
12. Schimmer, A. D. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice Cancer Res. 2004, 64 (20) 7183-90
13. Martinez-Ruiz, G.; Maldonado, V.; Ceballos-Cancino, G.; Grajeda, J. P.; Melendez-Zajgla, J. Role of Smac/DIABLO in cancer progression J. Exp. Clin. Cancer Res. 2008, 27, 48
14. Wang, S. Design of small-molecule Smac mimetics as IAP antagonists Curr. Top. Microbiol. Immunol. 2011, 348, 89-113
15. Wang, H. Y.; Guo, Q. Q.; Jiang, Y. F.; Liu, E. G.; Zhao, Y. X.; Wang, H. X.; Li, Y. P.; Huang, Y. Z. Co-delivery of Cell-permeable Chimeric Apoptosis AVPIR8 Peptide/p53 DNA for Cocktail Therapy Adv. Funct. Mater. 2013, 23 (48) 6068-75
16. Schmidt, N.; Mishra, A.; Lai, G. H.; Wong, G. C. Arginine-rich cell-penetrating peptides FEBS Lett. 2010, 584 (9) 1806-13
17. Pan, L.; He, Q.; Liu, J.; Chen, Y.; Ma, M.; Zhang, L.; Shi, J. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles J. Am. Chem. Soc. 2012, 134 (13) 5722-5
18. Igney, F. H.; Krammer, P. H. Death and anti-death: tumour resistance to apoptosis Nat. Rev. Cancer 2002, 2 (4) 277-88
19. Yang, X.; Fraser, M.; Moll, U. M.; Basak, A.; Tsang, B. K. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway Cancer Res. 2006, 66 (6) 3126-36
20. Carter, B. Z.; Mak, D. H.; Schober, W. D.; Koller, E.; Pinilla, C.; Vassilev, L. T.; Reed, J. C.; Andreeff, M. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML Blood 2010, 115 (2) 306-14
21. Zhao, J.; Jin, J.; Zhang, X.; Shi, M.; Dai, J.; Wu, M.; Wang, R.; Guo, Y. Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo Cancer Gene Ther. 2006, 13 (4) 420-7
22. Pan, M. H.; Huang, Y. T.; Ho, C. T.; Chang, C. I.; Hsu, P. C.; Sun Pan, B. Induction of apoptosis by Meretrix lusoria through reactive oxygen species production, glutathione depletion, and caspase activation in human leukemia cells Life Sci. 2006, 79 (12) 1140-52
23. Furuhata, M.; Kawakami, H.; Toma, K.; Hattori, Y.; Maitani, Y. Design, synthesis and gene delivery efficiency of novel oligo-arginine-linked PEG-lipids: effect of oligo-arginine length Int. J. Pharm. 2006, 316 (1-2) 109-16
24. Ito, T.; Sun, L.; Bevan, M. A.; Crooks, R. M. Comparison of nanoparticle size and electrophoretic mobility measurements using a carbon-nanotube-based coulter counter, dynamic light scattering, transmission electron microscopy, and phase analysis light scattering Langmuir 2004, 20 (16) 6940-5
25. Shabbits, J. A.; Hu, Y.; Mayer, L. D. Tumor chemosensitization strategies based on apoptosis manipulations Mol. Cancer Ther. 2003, 2 (8) 805-13
26. Yu, Z.; Schmaltz, R. M.; Bozeman, T. C.; Paul, R.; Rishel, M. J.; Tsosie, K. S.; Hecht, S. M. Selective tumor cell targeting by the disaccharide moiety of bleomycin J. Am. Chem. Soc. 2013, 135 (8) 2883-6
27. Breen, L.; Heenan, M.; Amberger-Murphy, V.; Clynes, M. Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines Anticancer Res. 2007, 27 (3A) 1361-4
28. Putt, K. S.; Chen, G. W.; Pearson, J. M.; Sandhorst, J. S.; Hoagland, M. S.; Kwon, J. T.; Hwang, S. K.; Jin, H.; Churchwell, M. I.; Cho, M. H.; Doerge, D. R.; Helferich, W. G.; Hergenrother, P. J. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy Nat. Chem. Biol. 2006, 2 (10) 543-50